Anti-Helicobacter pylori Therapy Benefits Those at High Risk for Gastric Cancer
Researchers found anti-Helicobacter pylori therapy had a long-term beneficial effect among a population at elevated risk for gastric cancer.
Researchers found anti-Helicobacter pylori therapy had a long-term beneficial effect among a population at elevated risk for gastric cancer.
Improving treatment in H pylori infection could lead to better outcomes in peptic ulcer disease, gastric cancer, gastric lymphoma, and functional dyspepsia.
A team of investigators created a deep learning-based decision support algorithm to identify the presence of Helicobacter pylori in gastric biopsy specimens.
A team of investigators conducted a study to determine the effectiveness of 2 new stool-based enzyme-linked assays to identify the presence of H pylori antigen.
Investigators of the retrospective cohort study evaluated adherence to guideline-supported eradication testing for Helicobacter pylori infection.
A global consensus meeting was convened to go over current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for the prevention of gastric cancer (GC).
Prescription of Helicobacter pylori eradication therapy within 1 year of gastric cancer treatment reduces the risk of later metachronous lesion development.
Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.
A novel rifabutin-based triple therapy (RHB-105) is effective for eradication of Helicobacter pylori, with eradication rates unaffected by resistance to clarithromycin or metronidazole.
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.